Medicine and Dentistry
Chemoradiotherapy
84%
Esophageal Cancer
77%
Radiation Therapy
66%
Neoplasm
36%
Overall Survival
22%
Rectum Cancer
22%
Positron Emission Tomography
22%
Malignant Neoplasm
22%
Recurrent Disease
17%
Surgery
14%
Proton Therapy
14%
Positron Emission Tomography-Computed Tomography
14%
Arm
13%
Brachytherapy
12%
Esophagectomy
11%
Squamous Cell Carcinoma
11%
Lymph Node
11%
Systematic Review
10%
Radiation Treatment Planning
10%
Prognostic Factor
10%
Positron Emission Tomography
9%
Disease Free Survival
8%
Computer Assisted Tomography
8%
Bevacizumab
8%
Adenocarcinoma
8%
Capecitabine
7%
Treatment Planning
7%
Neoadjuvant Therapy
7%
Cardiac Fibrosis
7%
Quality of Life
6%
Oxaliplatin
6%
Esophagus
6%
Cardiotoxicity
6%
Esophagus Tumor
6%
Radiation Therapy Planning
5%
Prospective Study
5%
Pelvis
5%
Tumor Progression
5%
Randomized Controlled Trial
5%
Hazard Ratio
5%
Adjuvant Chemoradiotherapy
5%
Adjuvant Therapy
5%
Esophagus Carcinoma
5%
Female Genital Tract Cancer
5%
Neoadjuvant Chemotherapy
5%
Endometrial Cancer
5%
Cervical Cancer
5%
Nurse
5%
Shared Decision Making
5%
Retroperitoneal Lymph Node Dissection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Esophagus Cancer
92%
Malignant Neoplasm
32%
Overall Survival
26%
Neoplasm
20%
Cardiotoxicity
18%
Recurrent Disease
16%
Capecitabine
16%
Rectum Cancer
15%
Chemotherapy
14%
Squamous Cell Carcinoma
11%
Carboplatin
10%
Paclitaxel
10%
Oxaliplatin
10%
Efficacy Study
10%
Bevacizumab
10%
Disease Free Survival
9%
Disease
9%
Adenocarcinoma
7%
Heart Muscle Fibrosis
7%
Fluorouracil
6%
Randomized Controlled Trial
6%
Adjuvant
6%
Liver Metastasis
5%
Breast Cancer
5%
Stomach Cancer
5%
Chronic Obstructive Lung Disease
5%
Troponin T
5%
Cisplatin
5%
Uterine Cervix Carcinoma
5%
Biological Marker
5%
Remission
5%
Heart Injury
5%
Prospective Cohort Study
5%
Keyphrases
Esophageal Cancer
36%
Neoadjuvant Chemoradiotherapy (nCRT)
28%
Radiotherapy
20%
Cancer Patients
13%
Radiation Dose
13%
Lung
12%
Surgery Alone
10%
CROSS Trial
10%
Neoadjuvant Bevacizumab
10%
Capecitabine
10%
Phase II Study
10%
Definitive Chemoradiation
10%
Cardiac Toxicity
10%
Pneumonia
10%
Proton Radiotherapy
9%
Radical Surgical Treatment
7%
Overall Survival
6%
Geographic Miss
6%
Radiation Therapy
6%
Chemoradiotherapy
6%
Chemoradiation
5%
Cardiac Events
5%
Esophagectomy
5%
Cancer Survivors
5%
High-sensitive Troponin
5%
Concurrent Chemoradiotherapy
5%
Surgery Groups
5%
Locoregional Control
5%
Radical Treatment
5%
Prognostic Impact
5%
Sexual Rehabilitation
5%
Clinician Preference
5%
Intraoperative Brachytherapy
5%
RAPIDO
5%
Microscopic Tumors
5%
Advanced Vulvar Cancer
5%
Squamous Cell Cancer
5%
Proton
5%
Vulvar Cancer
5%
Prospective Cohort Study
5%
Therapeutic Impact
5%
Motion Robustness
5%
Pathological Examination
5%
Follow-up Time
5%
Cardiac Damage
5%
Lymph Node Harvest
5%
Gynecological Cancer
5%
Efficacy Study
5%
Esophagus
5%
Extensive Surgery
5%
